Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226234 | 0.85 | KMT2A (0.71) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL13638129 | 0.85 | KMT2A (0.71) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL5519031 | 0.83 | KMT2A (0.69) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL3319719 | 0.83 | SIGMAR1 (0.64) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL278653 | 0.82 | SIGMAR1 (0.69) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL6742979 | 0.82 | SIGMAR1 (0.69) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL14407770 | 0.82 | SIGMAR1 (0.69) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL16226907 | 0.82 | KMT2A (1.00) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL16226336 | 0.82 | KMT2A (1.00) | KMT2AMEN1KDM4ESIGMAR1MC4R | |
| SCHEMBL16227228 | 0.82 | KMT2A (1.00) | KMT2AMEN1KDM4ESIGMAR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
| WO-2015092819-A2 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5- AMINE | NEKTAR THERAPEUTICS (INDIA) PVT. LTD. (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092819-A2 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5- AMINE | NEKTAR THERAPEUTICS (INDIA) PVT. LTD. (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | KMT2A 464/4885MEN1 1531/4885KDM4E 1078/4885 |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | KMT2A 464/4885MEN1 1531/4885KDM4E 1078/4885 |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | KMT2A 464/4885MEN1 1531/4885KDM4E 1078/4885 |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | KMT2A 464/4885MEN1 1531/4885KDM4E 1078/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | KMT2A 3784/4885MEN1 3480/4885KDM4E 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.